Contraceptive Drugs Market (By Product: Oral, Pills, Intrauterine Devices (IUD), Condoms, Vaginal Ring, Subdermal Implants, Injectable, Others: By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel & NGOs, Others: By Age Group: 15–24 years, 25–34 years, 35–44 years, Above 44 years)- Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024 – 2033
The global contraceptive drugs market size was valued at USD 16.94 billion in 2023 and it is expected to hit around USD 30.06 billion by 2033, poised to grow at a CAGR of 5.9% from 2024 to 2033.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The U.S. contraceptive drugs market size was estimated at USD 4.77 billion in 2023 and is predicted to be worth around USD 8.92 billion by 2033, at a CAGR of 6.5% from 2024 to 2033.
North America dominated the contraceptive drugs market in 2023. The growth of contraceptive drugs market in North America region is being driven by growing awareness about contraceptive pills among patients. According to Centers for Disease Control estimates, 14% of women aged 15 to 49 will be using contraceptive drugs in 2020. In addition, different strategies adopted by market players are also driving the growth of North America contraceptive drugs market. According to data published by the Bill & Melinda Gates Foundation in 2022, the foundation plans to invest $280 million per year from 2024 to 2033 in developing innovative and latest contraceptive technologies, supporting family planning programs that reflect local community preferences.
Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. The Asia-Pacific contraceptive drugs market growth is attributed to the growing reimbursement policies. In addition, the rising childbearing population is also driving the growth of contraceptive drugs market in Asia-Pacific region. As per the report released by the United Nations Department of Economic and Social Affairs, the population was over 163 million in 2019. More than 56% of women in this category utilize contraception. As a result, the expansion of contraceptive drugs market in this region is expected in near future.
The rising number of unwanted births is a primary factor driving demand for contraceptive drugs, resulting in global contraceptive drugs market expansion. According to a March 2021 estimate from the United Nations Population Fund, the number of unplanned pregnancies in 115 low- and middle-income nations was 1.4 million in 2020. As a result of these figures, the global demand for contraceptive tablets is increasing, leading to the growth of the global contraceptive drugs market.
The key driver enhancing the global contraceptive drugs market’s growth is the increased focus of leading industry players and healthcare organizations on promoting awareness through public programs to expand access to contraceptive drug options. For example, HRA Pharma, a European pharmaceutical firm, established cooperation with Ibis Reproductive Health, a non-profit organization dedicated to improving women’s reproductive autonomy, in January 2017 to launch over-the-counter medications in the U.S.
During the projection period, the growth of the global contraceptive drugs market is likely to be driven by the approval, development, and commercialization of novel and long-lasting techniques. Agile Therapeutics, for example, created Twirla, a hormonal patch that was released in the 4th quarter of 2020 in the U.S. Teenagers’ desire for contraception has increased as a result of the introduction of low cost and generic medications and technologies. As a result, the global contraceptive drugs market growth is expected in coming years.
The global contraceptive drugs market’s rivalry is expected to heat up a several major competitors focus on expanding their product portfolios through collaborations and acquisitions. The contraceptive drugs market is likely to provide new market players as well as established market leaders with several chances. Furthermore, joint ventures, mergers, and partnerships aid in boosting the presence of companies in the global contraceptive drugs market, thus assisting in improving the contraceptive drugs market’s growth rate.
| Report Coverage | Details |
| Contraceptive Drugs Market Size in 2023 | USD 16.94 Billion |
| Contraceptive Drugs Market Size by 2033 | USD 30.06 Billion |
| Contraceptive Drugs Market Growth Rate from 2024 to 2033 | CAGR of 5.9% |
| Largest Market | North America |
| Fastest Growing Market | Asia-Pacific |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product, By Distribution Channel, and By Age Group |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
The oral contraceptive drugs segment has the largest revenue share in 2023. The oral contraceptive drugs demand and acceptance are gradually increasing, particularly in developing markets. This is owing to the clinical advantages of oral contraceptive drugs over other traditional techniques, as well as the reduced cost of these medications compared to other modern contraceptive drugs options. The number of women of reproductive age who use birth control tablets has climbed from roughly 97 million in 1994 to 151 million in 2019.
The vaginal ring segment is expected to reach remarkable growth from 2024 to 2033. The factors such as long product life cycle as well as cost effectiveness are driving the growth of the segment. The introduction of new products and the ease of use of vaginal rings are projected to boost demand for these birth control techniques. Annovera, a reusable silicone ring that protects against unplanned pregnancy for up to a year, received Food and Drug Administration approval and five-year market monopoly as a novel chemical entity in September 2018 and will be commercially introduced in the 1st quarter of 2020.
The retail pharmacy segment accounted largest revenue share in 2023. This is attributed to rising demand for contraceptive pills among the general public as well as increased awareness of various contraceptive drugs options. Birth control tablets are sold over the counter in various nations. As a result, customers are increasingly turning to retail pharmacies to obtain birth control tablets. Furthermore, favorable regulations have contributed to the expansion of the segment.
The online distribution channel segment is projected to grow at fastest rate during the forecast period. The increased usage of over-the-counter solutions, coupled with numerous online discounts and offers to entice clients, is ascribed to the larger growth of online channels.
Segments Covered in the Report
By Product
By Distribution Channel
By Age Group
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Contraceptive Drugs Market
5.1. COVID-19 Landscape: Contraceptive Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Contraceptive Drugs Market, By Product
8.1. Contraceptive Drugs Market, by Product, 2024-2033
8.1.1 Oral
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Lead Acid
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Intrauterine Devices (IUD)
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Condoms
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Vaginal Ring
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Subdermal Implants
8.1.6.1. Market Revenue and Forecast (2021-2033)
8.1.7. Injectable
8.1.7.1. Market Revenue and Forecast (2021-2033)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Contraceptive Drugs Market, By Distribution Channel
9.1. Contraceptive Drugs Market, by Distribution Channel, 2024-2033
9.1.1. Hospital Pharmacy
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Retail Pharmacy
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Clinics
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Online Channel
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Public Channel & NGOs
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Contraceptive Drugs Market, By Age Group
10.1. Contraceptive Drugs Market, by Age Group, 2024-2033
10.1.1. 15–24 years
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. 25–34 years
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. 35–44 years
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Above 44 years
10.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Contraceptive Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Age Group (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Distribution Channel (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Age Group (2021-2033)
Chapter 12. Company Profiles
12.1. Church & Dwight Co., Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Reckitt Benckiser Group Plc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Veru, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Organon Group of Companies
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Pfizer, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Teva Pharmaceutical Industries Ltd.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. The Cooper Companies, Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Mayer Laboratories, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Agile Therapeutics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. TherapeuticsmMD, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
